# SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study

> **NCT02967679** · PHASE2 · COMPLETED · sponsor: **MedDay Pharmaceuticals SA** · enrollment: 15 (actual)

## Conditions studied

- Chronic Inflammatory Demyelinating Polyneuropathy
- Peripheral Neuropathy
- Charcot-Marie-Tooth Disease
- Charcot-Marie-Tooth Disease Type 1A
- Charcot-Marie-Tooth Disease, Type 1B
- Anti-MAG Neuropathy

## Interventions

- **DRUG:** MD1003

## Key facts

- **NCT ID:** NCT02967679
- **Lead sponsor:** MedDay Pharmaceuticals SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-05
- **Primary completion:** 2019-03-18
- **Final completion:** 2019-03-18
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2020-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02967679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02967679, "SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02967679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*